Ayr Wellness ($AYRWF) On Track to Become Largest Scale Cannabis Producer in US
Ayr Wellness Inc (OTCMKTS:AYRWF, CNSX:AYR.A) announced itself as a major player among US multi-state operators (MSO), acquiring Liberty Health Sciences. LHS is an integrated “seed-to-sale” company that provides medical marijuana products to patients throughout Florida. The transaction was looking to expand Ayr’s philosophy of growing the best-in-class flower to the state of Florida. Ayr has aggressively moved into new states while acquisition prices have been relatively low. Ayr’s expansion has put the company on track to become the largest-scale cannabis producer in the USA.
🎥 Watch Midas Letter Films site tour of LHS here: TOP TO BOTTOM, SEED TO SALE
Ayr Wellness CEO Jonathan Sandelman has a deep history on Wall Street, translating very well for Ayr’s accretive deal flow. The company has always maintained positive EBITDA and cash flow since its SPAC introduction to public markets. This distinction from many other cannabis players has allowed the company to keep growing while access to capital in the weed stocks industry has become more limited.
“I think that being an 8 state operator with an excellent balance sheet and excellent financial discipline, we at Ayr are uniquely positioned because we won’t have massive overlap to be able to slingshot from an 8 state operator to one of the top operators.” – Ayr Wellness Inc CEO Jonathan Sandelman
With 1.2+ million sq. ft. of cultivation/processing facilities in development, Ayr Wellness has updated its 2022 guidance to forecast revenues of $800 million and adjusted EBITDA of $300 million.
Watch the full interview to learn about the Ayr CEO’s philosophy and growth strategies and why he thinks the cannabis industry is extremely undervalued.
Transcript
00:00 – Ayr Wellness CEO Jonathan Sandelman
00:49 – Ayr Wellness overview
01:21 – Ayr Wellness history
05:03 – Positive EBITDA & cashflow
10:47 – State regulations
Related Articles
Disclosure
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.
